“I use ‘disruptive’ in both its good and bad connotations. Disruptive scientific and technological progress is not to me inherently good or inherently evil. But its arc is for us to shape. Technology’s progress is furthermore in my judgment unstoppable. But it is quite incorrect that it unfolds inexorably according to its own internal logic and the laws of nature.”
Mr. Alejandro Esteban Weinstein Manieu was the Chief Executive Officer of CFR Pharmaceuticals from 2000 until 2014. Mr. Weinstein has been responsible for transforming the CFR Group from a local Chilean pharmaceutical company into a global family pharmaceutical company with a presence in 26 countries, 3 continents and double digit sales growth for over five years. Mr. Weinstein has been active in developing and managing several businesses and startups in the pharmaceutical industry and the healthcare sector, including Genomika Foundation, a stem cell research organization; Biomedical Research Consortium, a joint venture between a biotech R&D Company and a university; Vidacel and Banco de Vida, public and private stem cell banks in Chile; and several other joint ventures with local and foreign R&D companies. He served as a Non-Executive Director at Allergy Therapeutics plc in the UK from July 1, 2009 to October 18, 2014, Member of the Board of Uman pharma, Canada; OPV pharma in Vietnam and several other pharmaceutical companies.
Today, Mr. Weinstein resides in Switzerland, where he is a general partner of a private equity firm and a venture capital firm with investments in USA,Israel and Europe. He is also Board Member of Project Blue, aiming to discover an earth-like planet near Alpha Centauri.
Mr. Weinstein has a BA, is CPA certified, and attended the Owner/President Management Program (OPM) at the Harvard Business School.Last Updated: Aug 28, 2017, 3:26pm